MedTrace Logo

Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia

NCT02302469 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2025-11-28

No results posted yet for this study

Summary

The purpose of this study is to determine the recommended dose of lenalidomide in subjects with relapse and refractory Waldenstrom Macroglobulinemia.

Conditions

Interventions

DRUG

Revlimid

Three cohorts of subjects will be successively exposed to escalating doses of Lenalidomide (15, 20 and 25mg once daily on days 1-21 of a 28 day cycle).

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • TOURNILLAC Olivier, Dr · Centre Hospitalier CLERMOND FERRAND

  • MOREL Pierre, Dr · Centre Hospitalier de Lens

  • LELEU Xavier, Dr · CHRU LILLE

  • LEGOUILL Steven, Dr · Centre Hospitalier de NANTES

  • LEBLOND Véronique, Dr · APHP PARIS

  • BANOS Anne, Dr · Centre Hospitalier de BAYONNE

  • SALLES Gilles, Pr · Centre Hospitalier de LYON

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2017-03-31
Completion
2017-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02302469 on ClinicalTrials.gov